Why Is ELI LILLY AND CO (LLY) Stock Moving Today?

Eli Lilly and Co (LLY) stock is moving higher today as the company announced a deal to acquire AtaiBeckley for up to $3.8 billion. The acquisition, which includes a cash payment of $6.75 per share and a contingent value right tied to development milestones, positions LLY to expand its portfolio in mental health treatments. The deal underscores growing industry interest in psychedelic-based therapies for treatment-resistant depression and other conditions.

What Happened

Eli Lilly agreed to acquire AtaiBeckley in a transaction that could reach $3.8 billion, with the initial payment set at $6.75 per share in cash. The deal also includes a contingent value right of up to $2.50 per share, dependent on the progress of two key programs. The acquisition gives LLY access to a DMT-based nasal spray that has received FDA Breakthrough Therapy Designation. The transaction is expected to close in the third quarter of 2026. The deal was reported by multiple outlets, including Quartz, Bloomberg, and Reuters, highlighting the strategic shift by large pharmaceutical firms into the psychedelic drug space.

What The Data Shows

LLY stock has declined by 3.7% over the last eight sessions, falling from $1200.95 to $1156.63. The stock currently trades within its 52-week range of $623.78 to $1249.45. Recent insider transactions include a sale by Yuffa Ilya, an executive vice president, on June 10, 2026. Congressional activity shows several members, including Gilbert Cisneros and Ro Khanna, made purchases in early June. Unusual options activity was noted, with a notable put premium of $301K recorded in the last 36 hours. The 52-week tape on July 16 showed 6 fresh 52-week highs and 61 fresh 52-week lows.

What To Watch

The deal’s closing in Q3 2026 will be a key milestone to monitor. Investors should also track the progress of the DMT and other therapies through regulatory milestones, as these will determine the contingent value right payouts.